Analyst Price Target is GBX 0
This price target is based on 0 analysts offering 12 month price targets for Graft Polymer in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a NaN upside from the last price of GBX 0.
Current Consensus is
N/A
The current consensus among 0 polled investment analysts is to n/a stock in Graft Polymer. This N/A consensus rating has held steady for over two years.
Graft Polymer
Graft Polymer (UK) Plc is an innovative biotechnology company focused on developing intellectual property relating to the treatment of mental health and substance use disorders, and co-developing therapeutics for mental health disorders.
Our mission is to improve outcomes for individuals suffering from these conditions, with an initial focus on trauma-related mental health disorders, such as PTSD, which affects approximately 13 million adults in the U.S. and 20 million in US, UK, and key EU markets.
Read More